Atrium Therapeutics Launches with $270M
Atrium Therapeutics has officially launched with approximately $270 million in funding to develop RNA-based medicines for rare genetic heart conditions. The company, a spinoff from Novartis's acquisition of Avidity Biosciences, will advance precision cardiology programs using a targeted RNA delivery platform. Its lead candidates are expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy.
The new company is helmed by President and CEO Kathleen Gallagher, who previously served as Avidity's chief program officer. This leadership continuity signals a deep understanding of the underlying science as Atrium is built upon Avidity's foundational work in targeted RNA delivery. Atrium's technology utilizes Antibody Oligonucleotide Conjugates (AOCs) to deliver RNA therapies directly to heart tissue. This platform aims to overcome a significant hurdle in genetic medicine: precisely targeting muscle cells to address the root cause of diseases. The company's lead drug candidate for PRKAG2 syndrome, ATR 1072, is expected to have an Investigational New Drug (IND) application filed with regulators in the second half of 2026. A second candidate, ATR 1086 for PLN cardiomyopathy, is targeting an IND submission in 2027. These rare genetic conditions have no approved therapies that treat the underlying cause. PRKAG2 syndrome is estimated to affect 1,000 to 2,000 people in the United States, while pathogenic PLN variants impact an estimated 2,000 to 4,000 individuals in the country. The launch is a direct result of Novartis's approximately $12 billion acquisition of Avidity Biosciences, which was contingent on the spin-out of these early-stage precision cardiology programs. Avidity shareholders approved the merger and the creation of Atrium in February 2026.
